Microdosing Psilocybin for Depression

This double-blind randomized-controlled trial will assess the effects of two small doses of synthetic psilocybin (5mg) in capsule form each week for six weeks in people with depression.

With 266 participants and funding in the region of $5.6 million AUD, this is one of the largest psychedelic studies to take place in Australia to date.

Topic Depression Microdosing
Compound Psilocybin
Country Australia
Visit trial
Status Planned
Results Published No
Start date 01 November 2022
Chance of happening 79%
Phase Phase II
Design Blinded
Type Interventional
Generation Second
Participants 266
Sex All
Age 18- 99
Therapy No

Trial Details



NCT Number

Sponsors & Collaborators

Woke Pharmaceuticals
Woke Pharmaceuticals is an Australian biotech company developing novel psychedelic compounds.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.